PMID: 6396656Dec 1, 1984Paper

Evidence for isosorbide dinitrate (ISDN) promoting effect on prostacyclin release by the lung and prostacyclin implication in ISDN-induced inhibition of platelet aggregation in humans

Prostaglandins, Leukotrienes, and Medicine
P H RollandJ P Cano

Abstract

We investigated thromboxane B2 (TxB2), 6-keto-PGF1 alpha (6KPGF1 alpha reflecting prostacyclin), PGE2 and PGF2 alpha plasma levels; TxB2, PGE2 and PGF2 alpha platelet production and platelet aggregation response in ascending aorta (reflecting trans-pulmonary difference) and in venous coronary sinus (reflecting transcardiac difference) simultaneously in patients with ischemic heart disease, before and after right-atrial administration of 3 mg ISDN bolus. Transcardiac differences were scarce before as well as after ISDN administration. In aortic blood, ISDN administration into the right atria resulted in a significant increase in prostacyclin and PGF2 alpha plasma levels (472% and 242%, respectively), a decrease of both PGE2 plasma level (-173%) and PGE2 platelet production (-485%) and a marked lowering of platelet aggregation response to ADP, concomittantly. In contrast, TxB2-related features were poorly affected by ISDN. In coronary sinus blood, the aortic increase in 6KPGF1 alpha and PGF2 alpha plasma levels was detected to a lower extent whereas the characteristics of platelet aggregation had returned to control levels. By contrast, PGE2 plasma level (-191%) and PGE2 platelet production (-133%) were lower than prior ISDN admi...Continue Reading

References

Sep 1, 1979·Lancet·H SinzingerK Silberbauer
Jan 1, 1978·Annual Review of Biochemistry·B SamuelssonC Malmsten
Sep 28, 1978·The New England Journal of Medicine·L D Hillis, E Braunwald
May 18, 1978·The New England Journal of Medicine·P Needleman, G Kaley
Jun 29, 1978·Nature·S MoncadaJ R Vane
Jun 1, 1978·Pharmacological Research Communications·A SzczeklikJ Mruk
May 1, 1982·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·S Moncada
Jan 1, 1984·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·P H RollandA Serradimigni
Jan 1, 1980·The American Journal of Cardiology·E MorcillioB Pitt
Mar 1, 1981·The Journal of Clinical Investigation·R I LevinK Tack-Goldman
Mar 1, 1981·The Journal of Clinical Investigation·J G GerberA S Nies
Apr 23, 1981·The New England Journal of Medicine·R M RobertsonJ A Oates
Nov 1, 1981·Prostaglandins·E Christ-Hazelhof, D H Nugteren
Apr 1, 1982·The American Journal of Cardiology·G G SerneriL Scarti
Aug 1, 1982·The American Journal of Cardiology·Y YuiT Murakami
Apr 1, 1982·Prostaglandins·I A BlairC T Dollery
Apr 1, 1982·American Heart Journal·E S Kirk, E H Sonnenblick

❮ Previous
Next ❯

Citations

Apr 15, 1987·Thrombosis Research·G G Neri SerneriG F Gensini
Dec 1, 1991·Trends in Cardiovascular Medicine·J S Stamler, J Loscalzo
Feb 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·D SalveminiJ Vane
Dec 1, 1994·British Heart Journal·R AndrewsS Heptinstall
Dec 4, 2012·Best Practice & Research. Clinical Gastroenterology·Annalisa BrunoPaola Patrignani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.